The addition of an IL-1-inhibiting antibody to the CAF pre-treatment step resulted in an inhibition of this effect, demonstrating that the CAFs induced tumor spheroid growth by secreting IL-1β (Fig. 4b). Here, IL1A is linked to neoplasm.